DBT-BIRAC-GCI supported Serum Institute of India for the first indigenously development of human papillomavirus vaccine (HPV)-- “CERVAVAC," against the cervical cancer in women
Patents
Nil
Outcome / Output
Considering the development of the indigenous HPV vaccine, India has the capacity to achieve success in the Cervical Cancer Elimination goal for 90% of coverage among girls up to 15 years old. With the introduction of the indigenous vaccine, the cost barrier being addressed.
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.
Serum Institute of India
Acces sibility Controls